Atea Pharmaceuticals, Inc.

NASDAQ•AVIR

執行長: Dr. Jean-Pierre Sommadossi Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2020-10-30

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

聯絡資訊

225 Franklin Street, Suite 2100, Boston, MA, 02110, United States

857-284-8891

ateapharma.com

市值

$476.57M

本益比 (TTM)

-3.0

17.9

股息率

52周最高

$6.45

52周最低

$2.46

52周範圍

91%

排名45Top 56.8%

3.6

F-Score

改良版 Piotroski 分析

基於 7 年期基本面

疲弱 • 3.6 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2019-2025

財務儀表板

Q4 2025 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.57+0.00%

近4季度走勢

自由現金流

-$28.22M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

HCV Phase 3 Trials Progressing C-BEYOND fully enrolled; C-FORWARD enrollment expected complete YE 2026; NDA targeted March 2027.

Net Loss Narrows Significantly Net loss decreased $10.0 M to $(158.3) M in 2025; R&D spend increased slightly to $148.0 M.

Cash Position Strong Cash, equivalents, and securities totaled $301.8 M on December 31, 2025, sufficient through 2027.

Workforce Reduction Completed 25% workforce reduction in Q1 2025 expected to yield $15.0 M aggregate cost savings through 2027.

關注風險

High Dependence on HCV Candidate Business highly dependent on successful HCV regimen development, approval, and commercialization; failure causes significant harm.

Need Substantial Future Financing Expect substantial operating expenses; failure to obtain necessary capital could delay or terminate product development efforts.

Regulatory Approval Unpredictable Regulatory approval processes are lengthy, expensive, and inherently unpredictable; failure to obtain approval seriously harms business.

Intellectual Property Litigation Risk Facing patent challenges from Gilead Sciences regarding bemnifosbuvir; adverse ruling requires licensing or halts commercialization.

未來展望

Targeting HCV NDA Submission Targeting submission of HCV regimen NDA to FDA in March 2027, pending successful completion of Phase 3 trials.

Initiate HEV Phase 1 Study Anticipate initiating clinical development of AT-587 for chronic HEV with a first-in-human Phase 1 study mid-2026.

Cash Funds Operations Through 2027 Current cash position of $301.8 M is expected to fund planned operations through the end of 2027.

Merck Milestone Payment Anticipated Next $10.0 M Merck milestone payment anticipated due upon acceptance of HCV regimen NDA in H1 2027.

同行對比

營業收入 (TTM)

VNDA

$216.11M

+8.7%

ARCT

$74.12M

-46.4%

ENTA

$66.98M

+0.6%

毛利率 (最新季度)

ENTA

100.0%

+0.0pp

PRQR

100.0%

+0.0pp

VNDA

93.3%

+0.1pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
VTYX	$1.00B	-9.4	-48.1%	4.7%
OMER	$793.38M	-6.2	57.3%	103.2%
ALLO	$539.35M	-2.9	-57.1%	18.0%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月11日

每股收益:-$0.56

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料